Home
PSTV
PSTV News

Latest PLUS THERAPEUTICS Inc. (PSTV) News on April 26, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

Zacks

2 days ago

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Zacks

3 days ago

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

GlobeNewswire

3 days ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

GlobeNewswire

11 days ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Plus (PSTV) Upgraded to Buy: Here's What You Should Know

Zacks

25 days ago

Plus (PSTV) Upgraded to Buy: Here's What You Should Know

Thomson Reuters StreetEvents

a month ago

Q4 2024 Plus Therapeutics Inc Earnings Call

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

a month ago

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates

Zacks

a month ago

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

GlobeNewswire

a month ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug

Zacks

a month ago

PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug

Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?

Insider Monkey

a month ago

Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?

MT Newswires

a month ago

Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

GlobeNewswire

a month ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

GlobeNewswire

a month ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

ACCESS Newswire

2 months ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

GlobeNewswire

2 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday

Insider Monkey

2 months ago

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday

PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy

Zacks

2 months ago

PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy

MT Newswires

2 months ago

Plus Therapeutics' Brain Cancer Therapy Shows Promise in Early-Stage Study; Shares Rise

FDA ODD given to Plus Therapeutics’ injectable radiotherapy

Pharmaceutical Technology

2 months ago

FDA ODD given to Plus Therapeutics’ injectable radiotherapy

MT Newswires

2 months ago

Top Premarket Gainers

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

GlobeNewswire

2 months ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

MT Newswires

2 months ago

Plus Therapeutics Gets FDA Orphan Drug Designation for Rhenium Obisbemeda in Lung Cancer; Shares Surge

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

GlobeNewswire

2 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics Announces New Employment Inducement Grants

GlobeNewswire

2 months ago

Plus Therapeutics Announces New Employment Inducement Grants

MT Newswires

2 months ago

Plus Therapeutics Expects $15 Million in Gross Proceeds From Private Placement of Units; Shares Fall

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

GlobeNewswire

2 months ago

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Zacks

2 months ago

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

GlobeNewswire

2 months ago

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

GlobeNewswire

2 months ago

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

GlobeNewswire

2 months ago

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

GlobeNewswire

2 months ago

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

4 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 12/10/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 12/09/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 12/06/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 12/05/2024

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

5 months ago

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 12/04/2024

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

GlobeNewswire

5 months ago

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 12/03/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 12/02/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/29/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/27/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/26/2024

CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis

Medical Device Network

5 months ago

CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

GlobeNewswire

5 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/25/2024

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

GlobeNewswire

5 months ago

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/22/2024

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

GlobeNewswire

5 months ago

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/21/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/20/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/19/2024

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/18/2024

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/15/2024

Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

GuruFocus.com

5 months ago

Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

5 months ago

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/14/2024

ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates

Zacks

5 months ago

ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/13/2024

Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates

Zacks

5 months ago

Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 11/11/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 11/08/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 11/07/2024

MT Newswires

6 months ago

Plus Therapeutics, SpectronRx Collaborate to Manufacture Rhenium Obisbemeda Radiotherapy

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

GlobeNewswire

6 months ago

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 11/06/2024

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

GlobeNewswire

6 months ago

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 11/05/2024

Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates

Zacks

6 months ago

Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 11/04/2024

MT Newswires

6 months ago

Plus Therapeutics Gets Additional Time to Regain Compliance With Nasdaq Listing Requirement

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 11/01/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/31/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/30/2024

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

GlobeNewswire

6 months ago

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/29/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/28/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/25/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/24/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/23/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/22/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/21/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/18/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/17/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/16/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/15/2024

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 10/14/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 10/11/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 10/10/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 10/09/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 10/08/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 10/07/2024

MT Newswires

7 months ago

Plus Therapeutics Files $100 Million Mixed Shelf

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 10/04/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 10/03/2024

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 10/02/2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting

GlobeNewswire

7 months ago

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting

Share on Social Networks: